Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy

Abstract

Treatment with tezepelumab reduced exacerbations, improved lung function, and reduced type 2 biomarkers versus placebo in patients with severe, uncontrolled asthma with or without perennial allergy, further supporting its efficacy in a broad population of patients with severe, uncontrolled asthma.